The present study was aimed to prove the hypothesis that inactivation of the TGF-β signaling pathway in the tumor microenvironment exerts a positive synergistic effect on PD-1 antibody treatment combined with RFA against PLC. This evidence concerns the gene HSPG2 and neoplasm.